Published Online
on March 24, 2008

A more recent version of this article appeared on May 1, 2008

This Article Full Text (PDF) Data Supplement All Versions of this Article: 51/5/1318    most recent HYPERTENSIONAHA.107.098772v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bodineau, L. Articles by Llorens-Cortes, C. Search for Related Content PubMed PubMed Citation Articles by Bodineau, L. Articles by Llorens-Cortes, C. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information High Blood Pressure Related Collections Animal models of human disease Other hypertension Related Article

Submitted on July 27, 2007
Revised on August 24, 2007

Orally Active Aminopeptidase A Inhibitors Reduce Blood Pressure. A New Strategy for Treating Hypertension

Laurence Bodineau; Alain Frugière; Yannick Marc; Nicolas Inguimbert; Céline Fassot; Fabrice Balavoine; Bernard Roques; and Catherine Llorens-Cortes^*

From the Inserm (L.B., A.F., Y.M., C.F., C.L-C.), U 691, Paris, France; Collège de France (L.B., A.F., Y.F., C.F., C.L-C.), Paris, France; Université Pierre et Marie Curie-Paris VI (L.B., A.F., Y.M., C.F., C.L-C.), Paris, France; from the Inserm (N.I., B.R.), U640, Paris, France; Université Paris V (N.I., B.R.), Paris, France; from the Quantum Genomics (F.B.), Massy, France.

^* To whom correspondence should be addressed. E-mail: c.llorens-cortes{at}college-de-france.fr.

Abstract—Overactivity of the brain renin-angiotensin system has been implicated in the development and maintenance of hypertension. We reported previously that angiotensin II is converted to angiotensin III by aminopeptidase A in the mouse brain. We then used specific and selective aminopeptidase A inhibitors to show that angiotensin III is one of the main effector peptides of the brain renin-angiotensin system, exerting tonic stimulatory control over blood pressure in hypertensive rats. Aminopeptidase A, the enzyme generating brain angiotensin III, thus represents a potential candidate central nervous system target for the treatment of hypertension. Given this possible clinical use of aminopeptidase A inhibitors, it was, therefore, important to investigate their pharmacological activity after oral administration. We investigated RB150, a dimer of the selective aminopeptidase A inhibitor, EC33, generated by creating a disulfide bond. This chemical modification allows prodrug to cross the blood-brain barrier when administered by systemic route. Oral administration of RB150 in conscious DOCA-salt rats inhibited brain aminopeptidase A activity, resulting in values similar to those obtained with the brains of normotensive rats, demonstrating the central bioavailability of RB150. Oral RB150 treatment resulted in a marked dose-dependent reduction in blood pressure in DOCA-salt but not in normotensive rats, with an ED₅₀ in the 1-mg/kg range, achieved in <2 hours and lasting for several hours. This treatment also significantly decreased plasma arginine-vasopressin levels and increased diuresis, which may participate to the blood pressure decrease by reducing the size of fluid compartment. Thus, RB150 may be the prototype of a new class of centrally active antihypertensive agents.

Key words: aminopeptidase A inhibitors • blood pressure • brain renin-angiotensin system • DOCA-salt rats • hypertension

Related Article:

Aminopeptidase A: Could It Be a Novel Target for Neurogenic Hypertension?

Anderson J. Ferreira and Mohan K. Raizada
Hypertension 2008 51: 1273-1274. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				B. S. Huang, M. Ahmad, J. Tan, and F. H. H. Leenen Chronic central versus systemic blockade of AT1 receptors and cardiac dysfunction in rats post-myocardial infarction Am J Physiol Heart Circ Physiol, September 1, 2009; 297(3): H968 - H975. [Abstract] [Full Text] [PDF]

				C. Claperon, I. Banegas-Font, X. Iturrioz, R. Rozenfeld, B. Maigret, and C. Llorens-Cortes Identification of Threonine 348 as a Residue Involved in Aminopeptidase A Substrate Specificity J. Biol. Chem., April 17, 2009; 284(16): 10618 - 10626. [Abstract] [Full Text] [PDF]

				A. J. Ferreira and M. K. Raizada Aminopeptidase A: Could It Be a Novel Target for Neurogenic Hypertension? Hypertension, May 1, 2008; 51(5): 1273 - 1274. [Full Text] [PDF]